OVERSEA CHINESE BANKING Corp Ltd trimmed its stake in Organon & Co. (NYSE:OGN - Free Report) by 50.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 135,500 shares of the company's stock after selling 135,500 shares during the quarter. OVERSEA CHINESE BANKING Corp Ltd owned about 0.05% of Organon & Co. worth $2,592,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Friedenthal Financial acquired a new position in shares of Organon & Co. in the 2nd quarter valued at about $769,000. Vanguard Group Inc. grew its stake in Organon & Co. by 0.6% during the first quarter. Vanguard Group Inc. now owns 30,789,850 shares of the company's stock worth $578,849,000 after buying an additional 192,613 shares during the period. Public Sector Pension Investment Board grew its stake in Organon & Co. by 8.0% during the second quarter. Public Sector Pension Investment Board now owns 565,866 shares of the company's stock worth $11,713,000 after buying an additional 41,954 shares during the period. O Shaughnessy Asset Management LLC increased its position in shares of Organon & Co. by 187.1% in the first quarter. O Shaughnessy Asset Management LLC now owns 39,758 shares of the company's stock worth $747,000 after acquiring an additional 25,909 shares in the last quarter. Finally, Wedge Capital Management L L P NC purchased a new position in shares of Organon & Co. in the 2nd quarter valued at $33,573,000. Institutional investors and hedge funds own 77.43% of the company's stock.
Analyst Ratings Changes
OGN has been the subject of a number of research reports. Evercore ISI raised shares of Organon & Co. to a "strong-buy" rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. downgraded Organon & Co. from a "neutral" rating to an "underweight" rating and upped their target price for the stock from $18.00 to $20.00 in a research report on Friday, September 6th.
Get Our Latest Report on OGN
Organon & Co. Stock Up 0.2 %
Shares of OGN stock traded up $0.03 on Wednesday, hitting $15.61. The stock had a trading volume of 2,284,991 shares, compared to its average volume of 2,250,676. The stock's 50 day moving average is $18.50 and its 200-day moving average is $20.02. The firm has a market capitalization of $4.02 billion, a price-to-earnings ratio of 3.10, a P/E/G ratio of 0.73 and a beta of 0.84. Organon & Co. has a 52-week low of $10.84 and a 52-week high of $23.10. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.
Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing analysts' consensus estimates of $0.90 by ($0.03). The firm had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The business's quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.78 EPS. As a group, research analysts expect that Organon & Co. will post 3.89 earnings per share for the current year.
Organon & Co. Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th will be issued a dividend of $0.28 per share. The ex-dividend date is Tuesday, November 12th. This represents a $1.12 annualized dividend and a yield of 7.17%. Organon & Co.'s dividend payout ratio is presently 22.22%.
About Organon & Co.
(
Free Report)
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
Further Reading
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
